We used the plasmid vector pGEX-2T for the expression of recombinant subunits of Shiga-like toxin II (SLT-II). The 5' terminus of the genes that code for either the SLT-IIA or SLT-IIB subunits was genetically fused to the 3' terminus of the gene coding for the enzyme glutathione S-transferase, which serves as a carrier in this expression system. The subunit genes were constructed synthetically by polymerase chain reaction, with appropriate restriction sites to permit in-frame downstream insertion of the genes. The resulting plasmids containing the A and B subunit genes were designated pFG1 and pFG2, respectively. Induction of Escherichia coli laboratory strains harboring pFG1 with isopropyl-13-D-thiogalactopyranoside (IPTG) SLTs (5, 6, 12) by assays using highly specific monoclonal antibodies, by detection of slt genes with either DNA probes or PCR, and by SLT neutralization tests. Enterohemorrhagic E. coli strains are directly responsible for a wide spectrum of diseases in both humans and animals (11). In humans, these manifestations range from asymptomatic infection to moderate diarrhea, increasing in severity to hemorrhagic colitis and even hemolytic uremic syndrome (HUS), a serious complication characterized by thrombocytopenia, hemolysis, and renal failure (12). HUS appears typically about 1 week after the onset of diarrhea. Diarrhea and HUS occur mainly in young children and also but more seldom in the elderly, consistent with the lack of immunity in these age groups (12) .
Enterohemorrhagic Escherichia coli strains produce either Shiga-like toxin I (SLT-I), SLT-II, or variants of the latter. While there are enterohemorrhagic E. coli strains producing only one, there are others producing various combinations of the above toxins (20) . A common structural principle of SLTs lies in the fact that they are all bipartite molecules composed of a single enzymatic A subunit and a multimer of receptor-binding B subunits (16) . Recently, three types of diagnostic tests have allowed detection of either E. coli strains which produce SLTs (10, 17, 23) or human serum responses to SLTs (5, 6, 12) by assays using highly specific monoclonal antibodies, by detection of slt genes with either DNA probes or PCR, and by SLT neutralization tests. Enterohemorrhagic E. coli strains are directly responsible for a wide spectrum of diseases in both humans and animals (11) . In humans, these manifestations range from asymptomatic infection to moderate diarrhea, increasing in severity to hemorrhagic colitis and even hemolytic uremic syndrome (HUS), a serious complication characterized by thrombocytopenia, hemolysis, and renal failure (12) . HUS appears typically about 1 week after the onset of diarrhea. Diarrhea and HUS occur mainly in young children and also but more seldom in the elderly, consistent with the lack of immunity in these age groups (12) .
There are indications of seroconversion in patients subsequent to infection; however, differentiation can be made with regard to the SLT type produced by the infectious E. * Corresponding author. coli strains. In patients suffering from HUS, increases in the titers of neutralizing antibodies against SLT-I were cited as evidence of recent infections (12) . In one of several studies demonstrating SLT-I-neutralizing antibodies, 10 of 15 patients with microbiological evidence of SLT-associated HUS showed a fourfold or even greater increase in SLT-I-neutralizing antibody titers, measured in cell cultures with Vero cells (12) . These results were also corroborated by Neut-RELISA, which is a modification of the receptor enzymelinked immunosorbent assay (ELISA) developed for detection of fecal SLT-I (5). Unlike patients suffering from infections with SLT-I-producing E. coli, HUS patients infected with SLT-II-producing E. coli do not show seroconversion. Caprioli et al. (6) detected high SLT-II-neutralizing activity in the serum of only 1 of 47 HUS patients, although SLT-II-producing E. coli could be cultured from stool samples of the majority of these patients. From the serological findings obtained from analyses of pooled commercial immunoglobulins to the effect that anti-SLT-I but not anti-SLT-II antibodies were present, it was assumed that the incidence of anti-SLT-II antibodies was strikingly low in the population at large (1).
We were moved by two considerations to try to develop a new assay for detecting antibodies to SLT-II. Firstly, the neutralization test is cumbersome to perform and has not been standardized for PCR strategies for amplification of sit-IIB. The slt-IIB subunit gene and the subgenic fragment were cloned from the slt-II reference strain E. coli C600 (933W) by polymerase chain reaction (PCR) using synthetic oligonucleotides as primers (Fig. 1) . The nucleotide sequences of the primers were derived from the published gene sequences of slt-IH (20) . These primers were termed GK3 and GK4, and their nucleotide sequences have been reported recently, together with those of primers GK1 and GK2, for amplifying the A-subunit gene (8) . The 5' primer contained a BamHI restriction site, and the 3' primer contained an EcoRI site. For amplifying the slt-IIB subunit gene, the primers GK3 and GK4 were used as described previously (9), amplification of the subgenic fragment of slt-IIB being carried out with the primers GK6 and GK4. The PCR products were isolated by agarose gel electrophoresis, visualized by staining with ethidium bromide (8) , and purified with Gene Clean (Dianova, Hamburg, Germany).
Sequences of the 5' primers for amplifying sll-ILA/sub) and sit-IIB/subl. The amplification of slt-IL4/subl and slt-IIB! subl was carried out with newly synthesized 5' primers, termed GK5 and GK6 (Fig. 1) . The sequences of these primers were as follows: GK5, 5'-CCC GGA TCC TCC CGG GAG TlTT ACG-3'; GK6, 5 (21) , the incubation times being extended. Briefly, the soluble proteins were affinity purified with 500 ,ul of glutathione agarose beads (Sigma, Deisenhofen, Germany) by a batch procedure. After 2 h of incubation at room temperature in a rotation incubator, the glutathione beads were washed four times with PBS and collected by centrifugation at 500 x g for 10 s after each washing step. To elute the protein from the beads, the beads were incubated with 1 ml of 50 mM Tris HCl (pH 8.0)-5 mM glutathione (reduced) for 20 min and again collected by centrifugation at 500 x g for 10 s. The elution was repeated twice. Each supernatant was lyophilized overnight and diluted in 100 ,ul of H20. The dissolved protein was stored at -80°C. The protein concentration was determined by the method of Markwell et al. (15) . The yield of recombinant protein was approximately 500 ,g from a 500-ml culture.
SLT-H-neutralization test. Neutralization assays and immunoblot analyses were carried out with 213 serum samples which came from blood donors and laboratory staff (aged 19 to 63 years) and with 47 serum samples from children without diarrhea or HUS (aged 8 months to 9 years) who were hospitalized for other medical reasons (3). In addition, seven serum samples came from children with SLT-IIproducing E. coli 0157-associated HUS. From these patients, serum samples were available from the acute phase (1 week after the onset of diarrhea) and from the postacute phase (4 to 6 weeks after the onset of diarrhea) of the disease. SLT-neutralizing antibodies were detected by the method described by Karmali et al. (12) , with SLT-II preparations obtained from E. coli C600 (933W). Rabbit anti-SLT-I and -SLT-II antibodies have been described previously (9) . For the neutralization assay, the human serum samples were diluted geometrically from 1:5 to 1:2,560. Neutralization activities were categorized as follows: category 1, no neutralizing activity (titer of <1:5); category 2, low neutralizing activity (titer 1:5 to 1:160); category 3, high neutralizing activity ( Fig. 1 , we amplified the slt-IL4 and slt-IIB subunit genes by PCR, as described previously (8) , and in addition subgenic fragments of these genes. Figure 2 shows PCR amplification products ofslt-ILA (lane 1) Fig. 3 . Figure 3A , lanes 5 to 7, shows expression of GST (27.5 kDa) 1, 2, and 3 h after induction, and for comparative purposes, Fig. 3B , lanes 5 to 7, shows expression of GST + SLT-IIA (59.5 kDa). As negative controls, we employed whole-cell lysates of noninduced cells, harvested at the same time as the induced cells. There was no expression of foreign protein apparent (lanes 2 to 4 in Fig. 3A and B) . When these IPTG experiments were performed on E. coli H1469 harboring the plasmid pFG2 containing the whole slt-IIB subunit gene, the induction caused cell lysis, which resulted in a rapid decrease in A600 from 0.5 to 0.1 within 60 min. Consequently, after centrifugation no bacterial pellets were obtainable. Therefore we constructed subgenic fragments of the slt-IIB subunit gene in order to gain the fusion protein required. We used the primers GK6 and GK4, whose location within the slt-IIB gene is shown in Fig. 1 . This approach proved successful, as shown in Fig. 4 , lanes 5 and 6. Bacteria harboring the plasmid pFG4 were able to synthesize a 33.5-kDa protein in large quantities, which was the expected molecular mass of the fusion protein consisting of GST and SLT-IIB/SUB1. This protein could not be detected on SDS gels with noninduced cells. We also employed this strategy of constructing a fusion protein without the leader sequence for the A subunit using primers GK5 and GK2. We were unable to further increase the yield over that obtained with cells harboring the plasmid pFG1, which contains the whole A-subunit gene.
Purification of recombinant SLT-IIB/SUB1. The recombinant proteins could be purified by affinity chromatography of disrupted cells on immobilized glutathione. The purified 33.5-kDa GST + SLT-IIB/SUB1 protein is shown in Fig. 5 , lane 3. In order to remove the GST carrier from the fusion protein, cleavage was carried out with thrombin. As shown in Fig. 5 , lane 4, this approach yielded a band at 6 kDa, the expected size of the SLT-IIB/SUB1 fusion protein. Since Reactivity of rabbit and human sera with the fusion protein.
We used the SLT-IIB fusion protein purified from the E. coli pFG4 expression system as the antigen for immunoblot analysis. GST from E. coli transformed with the pGEX-2T vector and purified by affinity chromatography was applied as a control. These antigens were separated by SDS-PAGE and either stained or transferred to nitrocellulose for use in subsequent immunoblots. Figure 6A shows a stained gel, with the GST in lane 1 and the SLT-IIB fusion protein in lane 2. With rabbit serum, reactivity occurred with the SLT-IIB fusion protein (Fig. 6B, lane 2) ; however, lane 1 does not reveal any reactivity at all, meaning that the response is indeed directed against the toxin and not against the GST. Preimmune serum showed no reactivity, while rabbit anti-SLT-I hyperimmune serum displayed a weak but visible band (not shown). Shown in Fig. 6C is an immunoblot analysis of a human serum sample with high SLT-II-neutralizing activity (titer, 1:640), which reveals a high degree of reactivity and specificity.
Comparison of the SLT-H cytotoxicity neutralization assay and immunoblot reactivity of human serum. Next we tested a total of 274 human serum samples by neutralization assay and immunoblot analysis to establish a correlation between these tests. These serum samples, originating from healthy adults, healthy children, and HUS patients, were duly categorized according to their neutralizing activity as having no measurable neutralization activity, low neutralizing titers, or high neutralizing titers. Table 1 shows the number of serum samples that fall into these three categories and indicates the reactivity of the serum samples in the immunoblot analysis with the recombinant SLT-IIB as the antigen. Obviously, as shown in Table 1 , the titers in the neutralization assay are either low (titers of 1:5 to 1:40) or very high (titers of > 1:320) for 75.9 and 4.4% of the serum samples tested, respectively. None of the samples tested yielded a titer between 1:80 and 1:320. A total of 19.7% had no neutralizing activity (titer of <1:5). All serum samples with high neutralizing activity reacted in the immunoblot analysis (Table 1) . Immunoblot strips of all 10 of the serum samples with high neutralizing activity from the blood donor group are depicted in Fig. 7A . As shown in Table 1 Healthy children (n = 47) 15 (0) 31 (1) 1 (1) HUS patients Acute phase (n = 7) 2 (0)
Total 54 (0) 208 (3) 12 (12) a Acute-and convalescent-phase serum samples are from the same patients.
b NA, neutralization assay; IB, immunoblot.
neutralizing activity and only 3 of 208 serum samples with low neutralizing activity reacted in the immunoblot test. The two blood donor serum samples from the group with low neutralization activity, together with eight representative nonreacting serum samples, are shown in Fig. 7B (7), and these may be measured in serodiagnosis and produce false-positive results. Secondly, the protein can be easily purified in any quantity required. Thirdly, the GST carrier has no immune reaction with the serum samples tested and was also shown by other investigators to be nonreactive in serological assays (2) . Fourthly, the SLT-IIB fusion protein is thought to be a better antigen than synthetic peptides. This has been demonstrated by our constructing three synthetic peptides representing different parts of the SLT-IIB subunit. We found that they are not reactive at all with sera containing high-level SLT-II-neutralizing antibodies (8a). A similar finding was recently reported by Levine et al. (13) . With serum samples from four patients with Shigella dysentenae type 1 infections and a positive ELISA result when the Shiga holotoxin was used, not one reacted with synthetic peptides which represent epitopes from the B subunit of Shiga holotoxin (13) .
What are the outlines of a serodiagnosis with SLT-IIB as the antigen? Patients with SLT-I-associated HUS have clearly been shown to have increases in titers of toxinneutralizing antibodies in serum that were considered to be of diagnostic value (11). It is not apparent whether this can be expected for SLT-II-associated HUS, and such a result is improbable. From the data of Caprioli et al. (6) , Ashkenazi et al. (1) , and Bitzan et al. (4) , it is expected that the significance of a diagnostic assay that measures seroconversion against SLT-II in patients with diarrhea or HUS will be low. We confirmed this when we compared acute-and convalescent-phase serum samples from seven HUS patients with SLT-II-associated disease. Only one of these serum samples showed a seroconversion. Direct detection of the pathogens in stool samples or a serodiagnosis based on lipopolysaccharide (3, 7) is considered superior. Of paramount interest is the question of prognostic value. Cross-infections occur within a family, in hospitals, in school day-care centers, and in homes for the elderly (11) , and analysis of the serum samples from those who are infected but are asymptomatic could help to clear up the point as to whether specific SLT-II antibodies provide protection. Moreover, by seroepidemiological studies the question of whether there is an age-related increase in seropositivity might well be clarified. If not, this would indicate that the toxin is produced in quantities so small that they are insufficient to generate antibody response, a phenomenon well-known from studies with tetanus toxin. Lastly, the immunoblot approach described here will enable large-scale analysis to be performed, so that the question of genetic restriction of SLT-II antibodies can also be answered.
